Andreas Hober

Dr. Andreas Hober

Department of Clinical Sciences, Karolinska Institutet, Stockholm, Sweden
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2019 in Science
Verified
Journal Article
Closed access
PDF file
MUMathias Uhlen
Mathias Uhlen
MKMax J. Karlsson
Max J. Karlsson
WZWen Zhong
Wen Zhong
ATAbdellah Tebani
Abdellah Tebani
CPChristian Pou
Christian Pou
PBPetter Brodin
Petter Brodin
A blood cell protein-expression atlas: Genome-wide analyses are increasingly providing resources for advances in basic and applied biomedical science. Uhlen et al. performed a global expression analysis of human blood cell types and integrated this data with data across all major human tissues and organs in the human protein atlas. This comprehensive compendium allows for classification of all human protein-coding genes with regard to their tissue- and cell-type distribution. Science , this issue p. eaax9198

26 November 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MUMathias Uhlen
Mathias Uhlen
MKMax J. Karlsson
Max J. Karlsson
AHAndreas Hober
Andreas Hober
ASAnne-Sophie Svensson
Anne-Sophie Svensson
JSJulia Scheffel
Julia Scheffel
ÅSÅsa Sivertsson
Åsa Sivertsson
A database provides information on the relative abundances and locations of human proteins that are predicted to be secreted.

8 October 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
Fredrik EdforsFredrik Edfors
Fredrik Edfors
AHAndreas Hober
Andreas Hober
KLKlas Linderbäck
Klas Linderbäck
GMGianluca Maddalo
Gianluca Maddalo
AAAlireza Azimi
Alireza Azimi
MUMathias Uhlen
Mathias Uhlen
There is a need for standardized validation methods for antibody specificity and selectivity. Recently, five alternative validation pillars were proposed to explore the specificity of research antibodies using methods with no need for prior knowledge about the protein target. Here, we show that these principles can be used in a streamlined manner for enhanced validation of research antibodies in Western blot applications. More than 6,000 antibodies were validated with at least one of these strategies involving orthogonal methods, genetic knockdown, recombinant expression, independent antibodies, and capture mass spectrometry analysis. The results show a path forward for efforts to validate antibodies in an application-specific manner suitable for both providers and users.

1 November 2021 in eLife
Verified
Journal Article
Open access
MJMichael Jahn
Michael Jahn
NCNick Crang
Nick Crang
MJMarkus Janasch
Markus Janasch
AHAndreas Hober
Andreas Hober
BFBjörn Forsström
Björn Forsström
EHElton Paul Hudson
Elton Paul Hudson
Bacteria must balance the different needs for substrate assimilation, growth functions, and resilience in order to thrive in their environment. Of all cellular macromolecules, the bacterial proteome is by far the most important resource and its size is limited. Here, we investigated how the highly versatile 'knallgas' bacterium Cupriavidus necator reallocates protein resources when grown on different limiting substrates and with different growth rates. We determined protein quantity by mass spectrometry and estimated enzyme utilization by resource balance analysis modeling. We found that C. necator invests a large fraction of its proteome in functions that are hardly utilized. Of the enzymes that are utilized, many are present in excess abundance. One prominent example is the strong expression of CBB cycle genes such as Rubisco during growth on fructose. Modeling and mutant competition experiments suggest that CO2-reassimilation through Rubisco does not provide a fitness benefit for heterotrophic growth, but is rather an investment in readiness for autotrophy.

18 December 2025 in Science
Verified
Journal Article
Closed access
MÁMaría Bueno Álvez
María Bueno Álvez
SBSofia Bergström
Sofia Bergström
JKJosefin Kenrick
Josefin Kenrick
EJEmil Johansson
Emil Johansson
MAMikael Aberg
Mikael Aberg
MUMathias Uhlen
Mathias Uhlen
The human blood proteome provides a holistic readout of health states through the assessment of thousands of circulating proteins. In this study, we present a pan-disease resource to enable the study of diverse disease phenotypes within a harmonized proteomics dataset. By profiling protein concentrations across 59 diseases and healthy cohorts, we identified proteins associated with age, sex, and body mass index, as well as disease-specific signatures. This study highlights shared and distinct protein patterns across conditions, demonstrating the power of a unified proteomics approach to uncover biological insights. The dataset, covering 8262 individuals and up to 5416 proteins, serves as an online resource for exploring disease-specific protein profiles and advancing precision medicine research.

8 November 2021 in eLife
Verified
Journal Article
Open access
AHAndreas Hober
Andreas Hober
KTKhue Hua Tran-Minh
Khue Hua Tran-Minh
DFDominic Foley
Dominic Foley
TMThomas McDonald
Thomas McDonald
JVJohannes Pc Vissers
Johannes Pc Vissers
Fredrik EdforsFredrik Edfors
Fredrik Edfors
Reliable, robust, large-scale molecular testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for monitoring the ongoing coronavirus disease 2019 (COVID-19) pandemic. We have developed a scalable analytical approach to detect viral proteins based on peptide immuno-affinity enrichment combined with liquid chromatography-mass spectrometry (LC-MS). This is a multiplexed strategy, based on targeted proteomics analysis and read-out by LC-MS, capable of precisely quantifying and confirming the presence of SARS-CoV-2 in phosphate-buffered saline (PBS) swab media from combined throat/nasopharynx/saliva samples. The results reveal that the levels of SARS-CoV-2 measured by LC-MS correlate well with their correspondingreal-time polymerase chain reaction (RT-PCR) read-out (r = 0.79). The analytical workflow shows similar turnaround times as regular RT-PCR instrumentation with a quantitative read-out of viral proteins corresponding to cycle thresholds (Ct) equivalents ranging from 21 to 34. Using RT-PCR as a reference, we demonstrate that the LC-MS-based method has 100% negative percent agreement (estimated specificity) and 95% positive percent agreement (estimated sensitivity) when analyzing clinical samples collected from asymptomatic individuals with a Ct within the limit of detection of the mass spectrometer (Ct ≤ 30). These results suggest that a scalable analytical method based on LC-MS has a place in future pandemic preparedness centers to complement current virus detection technologies.